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Summary
Mutations in the Plasmodium falciparum chloro-
quine (CQ) resistance transporter (PfCRT) can result
in verapamil-reversible CQ resistance and altered
susceptibility to other antimalarials. PfCRT contains
10 membrane-spanning domains and is found in the
digestive vacuole (DV) membrane of intraerythro-
cytic parasites. The mechanism by which PfCRT
mediates CQ resistance is unclear although it is
associated with decreased accumulation of drug
within the DV. On the permissive background of the
P. falciparum 106/1K76 parasite line, we used single-
step drug selection to generate isogenic clones con-
taining unique pfcrt point mutations that resulted in
amino acid changes in PfCRT transmembrane
domains 1 (C72R, K76N, K76I and K76T) and 9
(Q352K, Q352R). The resulting changes of charge
and hydropathy affected quantitative CQ susceptibil-
ity and accumulation as well as the stereospecific
responses to quinine and quinidine. These results,
together with a previously described S163R
mutation in transmembrane domain 4, indicate that
transmembrane segments 1, 4 and 9 of PfCRT
provide important structural components of a sub-
strate recognition and translocation domain.
Charge-affecting mutations within these segments
may affect the ability of PfCRT to bind different
quinoline drugs and determine their net accumula-
tion in the DV.
Introduction
The continuing burden of malaria has been aggravated by
the evolution and spread of Plasmodium falciparum resis-
tant to chloroquine (CQ) (Baird, 2005). Despite recent
advances in understanding the genetic basis for resis-
tance in P. falciparum, the molecular mechanism remains
uncertain. CQ accumulates in the parasite digestive
vacuole (DV), a lysosome-like organelle where host hae-
moglobin is digested to amino acids during the intraeryth-
rocytic stage of infection (Yayon et al., 1985; Goldberg
et al., 1990). Free haematin is released as a toxic
by-product of haemoglobin breakdown and is normally
sequestered as an inert microcrystalline form known as
haemozoin (Pagola et al., 2000). In the DV, CQ and other
quinolines are believed to bind haematin and inhibit the
formation of haemozoin (Sullivan et al., 1996), resulting in
the build-up of lethal drug–haematin complexes (Chou
and Fitch, 1980; Dorn et al., 1998).
A series of genetic mapping and allelic association
studies has shown that CQ resistance (CQR) arose by
mutations in the P. falciparum chloroquine resistance
transporter (PfCRT) protein (Fidock et al., 2000; Djimde
et al., 2001; Wootton et al., 2002). A putative member of
the drug/metabolite transporter (DMT) superfamily (Martin
and Kirk, 2004; Tran and Saier, 2004), PfCRT contains 10
predicted transmembrane domains (TMDs) and is local-
ized to the DV membrane of trophozoite-stage parasites
(Cooper et al., 2002). Although various haplotypes of
PfCRT exist in naturally CQ-resistant parasite popula-
tions, all forms show changes in at least 4 of 15 different
amino acid positions (Bray et al., 2005). Every such para-
site has so far been found to carry the charge-loss muta-
tion K76T, or, in a single documented case, K76N
(Huaman et al., 2004; Cooper et al., 2005). No other
mutation is completely associated with CQR on a global
scale, raising the question of the relative contribution of
other mutations to resistance per se, versus their role in
balancing endogenous protein function and accommodat-
ing the charge loss. PfCRT mutations are also thought to
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affect cross-resistance and the potency of structurally
diverse drugs that target the DV (Cooper et al., 2002;
Sidhu et al., 2002; Ferdig et al., 2004; Johnson et al.,
2004).
Models to explain CQR hinge on the observed
decrease in drug accumulation associated with mutant
PfCRT. Both sensitive and resistant parasites retain an
equal capacity for CQ–haematin binding, yet resistant
parasites have developed a mechanism to reduce CQ
accumulation at its site of action in the DV (Bray et al.,
1998; Saliba et al., 1998). Some reports have suggested
that altered drug accumulation results from an energy-
dependent CQ efflux mechanism (Krogstad et al., 1992;
Sanchez et al., 2004; 2005; Naude et al., 2005); others
have suggested passive efflux of diprotic CQ out of the
DV by a ‘charged drug leak’ mechanism (Warhurst, 2003;
Johnson et al., 2004; Bray et al., 2006). Experiments
using a yeast heterologous expression system have
shown that direct CQ-PfCRT binding may play a role in
altered CQ accumulation (Zhang et al., 2004).
The 106/1K76 line of P. falciparum is a CQ-sensitive
isolate containing six of seven PfCRT mutations charac-
teristic of many Old World CQ-resistant isolates (M74I-
N75E-A220S-Q271E-N326S-R372I), lacking only the
critical K76T mutation (Fidock et al., 2000). Earlier, we
reported the emergence of CQ-resistant parasites con-
taining novel K76N and K76I PfCRT mutations from
106/1K76 following single-step selection with CQ, demon-
strating a key role for the loss of the charged K76 residue
in the resistance mechanism (Cooper et al., 2002). We
also observed that mutant parasites carrying the K76I
mutation (106/176I line) exhibited stereoselective changes
in response to the isomers quinine (QN) and quinidine
(QD), suggesting drug–PfCRT binding as a component in
the mechanism of action of these drugs.
Here we report further results on the molecular basis of
PfCRT-mediated drug selectivity and sensitivity. We have
used single-step QN pressure to generate a panel of
resistant clones from the 106/176I line, each carrying a
single-point mutation resulting in an amino acid change in
PfCRT. In each case, gain of a critical lysine or arginine
residue was observed at a unique position in a TMD of the
PfCRT protein. We also demonstrate under single-step
CQ selection the emergence of the PfCRT K76T substi-
tution ubiquitous in CQR field isolates. Quantitative
changes in drug potency, stereoselectivity and CQ accu-
mulation were associated with these mutations. Our find-
ings implicate direct drug–PfCRT interactions in CQR and
in altered susceptibility to QN and QD.
Results
Selection with QN results in novel PfCRT second-site
suppressor mutations
Our previous pharmacological characterization of a 106/
176I mutant showed that this highly CQ-resistant line
exhibits an unusual degree of QN sensitivity (IC50 16 nM;
Table 1) (Cooper et al., 2002). To explore the effect of
PfCRT mutations on this sensitivity, we subjected 106/176I
parasites to additional single-step selection experiments
with 100 nM QN (Fig. 1A). These experiments produced
three populations of QN-resistant parasites that, when
evaluated by DNA sequencing, exhibited different novel
PfCRT mutations: C72R, Q352K and Q352R (lines
designated 106/172R-76I, 106/176I-352K and 106/176I-352R
respectively). No changes other than these mutations
were detected in the pfcrt or pfmdr1 sequences, and
analysis using the multicopy microsatellite marker PfRRM
(Su et al., 1998) confirmed that each clone was of identi-
cal provenance with the 106/176I (and also 106/1K76) line
(data not shown). The codon changes at position 72 (TGC
to CGC) and position 352 (CAA to AAA or CGA) produced
amino acid changes in predicted TMD 1 or TMD 9 of
PfCRT respectively.
Table 1. Effect of PfCRT mutations in the 106/1K76 line of P. falciparum on susceptibility to CQ, QN and QD, alone and in the presence of VP.*
Drug
Parasite line
Dd2† 106/1K76 106/176N‡ 106/176T‡ 106/176I‡ 106/172R-76I§ 106/176I-352K§ 106/176I-352R§
CQ 383  17 34  1.3 304  13¶ 445  11¶ 589  19¶ 34  1.0** 26  0.7** 50  2.2**
CQ + VP 41  1.4 30  0.9 39  1.5 35  0.8 41  1.2 38  1.0 28  1.2 34  1.8
QN 324  13 205  7.8 349  11¶ 382  22¶ 16  4.7¶ 168  10** 240  6.8** 170  9.1**
QN + VP 52  1.3 201  8.4 39  3.2 70  5.0 73  4.5 187  7.0 206  7.2 98  8.3
QD 187  8.0 57  5.6 65  4.9 112  6.3¶ 89  4.2¶ 52  3.8** 68  3.1** 48  2.5**
QD + VP 16  5.0 55  5.1 12  1.1 14  1.0 25  5.1 50  3.4 57  3.3 33  2.2
*IC50 values (nM) from [3H]-hypoxanthine incorporation measurements are reported as means  SEM from 4–18 independent assays. VP was
used at a fixed concentration of 0.9 mM.
†Control CQ-resistant line.
‡Lines selected with CQ pressure from 106/1K76.
§Lines selected with QN pressure from 106/176I.
¶Mean IC50 value significantly different from 106/1K76 parent line (P < 0.05).
**Mean IC50 value significantly different from 106/176I parent line (P < 0.05).
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Multiple immunoblots of parasite lysates were per-
formed to compare expression levels of PfCRT from
parental and derived mutant lines (Fig. 1B). These immu-
noblots showed small differences in PfCRT levels from
experiment to experiment, but the differences varied in
pattern among the lines and did not associate with drug
response. Similar results are reported from fresh field
isolates (Durrand et al., 2004). We attribute these obser-
vations to slight differences in the stage of the parasites at
harvesting.
Drug assays of the 106/172R-76I, 106/176I-352K and 106/
176I-352R lines confirmed their greatly reduced sensitivities
to QN relative to 106/176I parasites (Fig. 2A). Mean Hill
slope values derived from curve fit data of all QN-selected
lines were significantly steeper than that of the parent
106/176I line and differed from each other as well (F-test;
P < 0.05), suggesting a change in binding cooperativity
between QN and the different forms of PfCRT (data not
shown). We note that inferring a specific molecular
mechanism based on slope change is difficult because of
the complexities in associating PfCRT–drug interactions
with an assay outcome of [3H]-hypoxanthine incorporation
as a surrogate for cell death.
Drug assays showed the QN-selected lines had
returned to full CQ sensitivity (CQS) and had lost the
inverse relationship of stereospecific QN and QD poten-
cies we reported previously for the 106/176I parasite
(Table 1) (Cooper et al., 2002). The restoration of CQS in
a CQ-resistant line by an arginine substitution at position
72, or an arginine or a lysine substitution at position 352,
provides evidence for the importance of a critical positive
charge in PfCRT TMD 1 or 9 for CQS in addition to TMD
4 reported earlier (Johnson et al., 2004). We note that
106/176I-352R has an elevated CQ IC50 value (50 nM) for a
CQ-sensitive line and retains 30–40% verapamil (VP)
reversibility against CQ and QN, suggestive of an inter-
mediate CQR phenotype (Table 1).
In parallel with the above work, we also performed
single-step selection experiments with CQ on the 106/1K76
line (Fig. 1A). These experiments led to recovery of para-
sites with the PfCRT K76T mutation (106/176T line) in
addition to the 106/176I and 106/176N lines reported earlier
(Cooper et al., 2002) (Table 1). In common with the
QN-selected mutant lines, sequencing and genotyping
confirmed that the 106/176T line was derived from 106/1K76
and carried only one new mutation in pfcrt, and no
changes in the pfmdr1 sequence. Similarly, expression
levels of mutant PfCRT were comparable to that of
106/1K76 (Fig. 1B). Consistent with all CQ-resistant field
isolates, mutant 106/176T parasites displayed the
VP-reversible CQR phenotype (Table 1). Figure 2B illus-
trates the rightward shift of the sigmoidal CQ dose–
response curve that occurred with the K76T mutation. The
CQ dose–response curves from all three selected
CQ-resistant lines had slightly shallower, but statistically
significant changes (F-test; P < 0.05) in the Hill coeffi-
cients compared with 106/1K76, and differed from each
other as well (data not shown). These slope changes
suggest that the mutations again resulted in altered
binding cooperativity, in this case between PfCRT and
CQ. Relative to 106/1K76, 106/176T parasites also showed
significant decreases in QN and QD sensitivity, and onset
of VP sensitization (Table 1), demonstrating a critical role
of the PfCRT K76T field mutation in reduced sensitivity to
Fig. 1. Selection pathway of PfCRT mutants and immunoblot
analysis.
A. Selection of PfCRT mutant parasite lines from the 106/1K76 and
106/176I line. Mutations were selected by subjecting 109-1010
parasites to single-step 100 nM CQ (106/1K76) or QN (106/176I)
pressure.
B. Immunoblots show similar PfCRT expression levels in the
mutant parasite lines relative to 106/1K76. Lower blot is a loading
control, showing similar levels of P. falciparum a-tubulin. Protein
from equal numbers of synchronous trophozoites was separated on
12% SDS-PAGE and transferred to PVDF membrane. PfCRT and
a-tubulin II were detected by chemiluminescence using anti-PfCRT
or anti-a-tubulin II antibody. Molecular weight (kDa) ladders are
illustrated on the side of the membrane.
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multiple drugs. The susceptibilities of all mutant parasite
lines to the structurally unrelated sesquiterpene lactone
artemisinin were also determined. Similar to our earlier
observations (Cooper et al., 2002), small changes were
observed within the low nanomolar range. No trends were
observed between artemisinin sensitivity and specific
pfcrt mutations (data not shown). Finally, we have
observed that the drug susceptibility profiles of all pfcrt
mutant lines have remained stable after continuous
culture for many months in the absence of any drug pres-
sure (data not shown).
Ability of parasites to accumulate CQ is associated with
PfCRT mutations
CQ-resistant lines of P. falciparum limit the concentration
of CQ in their DVs (Krogstad et al., 1987). In confirma-
tion of this association, CQ-resistant lines 106/176T and
106/176I accumulate far less drug than the original
CQ-sensitive 106/1K76 line; Fig. 3 shows the relative
accumulations reduced by approximately 22- and eight-
fold, respectively, in the 1 h assay conditions of the
present study. With reversion of the mutant 106/176I lines
to CQ-sensitive phenotypes, CQ accumulation was
increased again but not to the levels of the original
106/1K76 line: parasites 106/176I-352R, 106/172R-76I and 106/
176I-352K each showed greater [3H]CQ mean counts than
their 106/176I parent CQ-resistant line (Fig. 3); of these,
however, only counts from the 106/176I-352K line were
found to differ significantly from those of the parent line
by t-test (P < 0.05). Although the correlation between CQ
IC50 values and accumulation of [3H]CQ may not be
linear among the lines tested, an overall relationship
between these two parameters is apparent. The trend
for a small twofold accumulation increase for 106/176I-352R
would also be consistent with its residual phenotype of
CQR noted above.
VP competitively inhibits the QN response of 106/176I
In addition to its unusual degree of susceptibility to QN,
106/176I is the only reported line of P. falciparum against
which QN is more potent than its diastereomer, QD
(Cooper et al., 2002) (Table 1). The reversal agent VP
normally chemosensitizes CQ-resistant parasites to CQ,
QN and QD (Kyle et al., 1990). However, VP surprisingly
acts as a QN inhibitor (increasing its IC50) in 106/176I,
despite potentiating the response to its isomer QD, as well
as to CQ, in the normal reported fashion (Table 1). To
Fig. 2. PfCRT position 76 and 352 mutations determine specific levels of QN and CQ susceptibility.
A. Changes in sensitivity to QN following selection of a Q352K or Q352R mutation within PfCRT TMD 9 in the 106/176I line. Data points on the
dose–response curves from [3H]-hypoxanthine incorporation assays represent mean  SEM from at least four independent experiments. Mean
IC50 values and Hill slopes derived from curve fitting were significantly different for each mutant (P < 0.5). Data for the QN-selected line
106/172R-76I (Table 1) is not illustrated for clarity.
B. Dose–response curves illustrating the changes in CQ sensitivity following selection of K76N, K76T or K76I mutations in PfCRT TMD 1 of
the 106/1K76 line. Data points represent mean  SEM of at least four independent experiments. Mean IC50 and Hill slope values were
significantly different for the curve fit from each mutant (P < 0.5).
Fig. 3. PfCRT mutations determine parasite CQ accumulation.
Mutations at positions 72, 76 and 352 of PfCRT affect the CQ
cellular accumulation ratio (CAR). Trophozoite-infected erythrocytes
were incubated in the presence of 50 nM [3H]CQ for 60 min. Single
asterisks indicate CAR differs significantly from the 106/1K76 parent
(P < 0.05). Double asterisks indicate CAR differs significantly from
the 106/176I parent (P < 0.05).
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further investigate the nature of this unique interaction, we
performed Schild analysis on the antagonistic properties
of VP against QN in the 106/176I line. Schild analysis tests
whether the rightward shifts in agonist (QN) dose–
response curves in the presence of incremental concen-
trations of antagonist (VP) fit a model of simple
competition between the two drugs for a common binding
or receptor site (Arunlakshana and Schild, 1959). A Schild
regression slope not significantly different from unity indi-
cates simple competition. Under these assumptions, the
KB, or antagonist equilibrium dissociation constant, is esti-
mated from the regression X-intercept. Schild analysis is
mathematically applicable only to the principles of drug
antagonism (Arunlakshana and Schild, 1959) and thus
was not used to study the potentiating effect of VP on CQ
in this and other parasite lines. We measured QN suscep-
tibility in a series of dose–response tests against 106/176I
in the presence of six concentrations of VP (Fig. 4A).
Regression fitting of the Schild data produced a linear plot
with a slope of unity [0.97; 95% confidence interval (CI) of
0.88–1.05], pointing to a competitive interaction between
QN and VP. The X-intercept predicts a dissociation con-
stant (KB) of 324 nM (95% CI of 289–358 nM) for VP and
its binding site (Fig. 4B). Combined with observations of
the stereospecific drug effect on QN and QD, these data
suggest a site of competitive interaction between QN and
VP is present at PfCRT in the 106/176I line.
PfCRT position 76 mutations alter interactions in
quinoline combinations
Dose combinations consisting of CQ and QN are reported
to act antagonistically in P. falciparum, both on parasite
morphology and in terms of fractional IC50 values (Stahel
et al., 1988; Fitch, 2004). To evaluate the influence of
PfCRT mutations on quinoline interactions, we tested the
effects of CQ, QN and QD in pair-wise combinations and
plotted the fractional IC50 data as isobolograms (Beren-
baum, 1978). The CQ:QN combination was slightly syn-
ergistic in the parent 106/1K76 line, slightly antagonistic in
106/176T and clearly synergistic against 106/176I, reflecting
the unusual QN sensitivity in this line (Fig. 5). In contrast,
the CQ:QD pair was antagonistic in all parasite lines,
regardless of PfCRT haplotype, indicating differences in
the molecular interactions with QN versus QD.
Stereoisomer drug pairs usually bind to the same
receptor molecule, but often with greatly different affinities
(Laduron, 1988; Triggle, 1996). Wesche and Black (1990)
demonstrated an additive interaction between the cin-
chona alkaloid stereoisomer pairs in CQ-sensitive and
CQ-resistant lines of P. falciparum. Similarly, in our
assays, the QN:QD combination was additive to slightly
synergistic with respect to 106/1K76 and 106/176T (Fig. 5);
isobolograms for 106/176N were qualitatively similar to
those of the 106/176T line (data not shown). In the 106/176I
line, however, QN:QD was synergistic, indicative of a
major and unique effect of the position 76 isoleucine. Yet
this effect is context-specific, as isobol trends for all
double mutants derived from 106/176I resembled the origi-
nal CQ-sensitive parent, 106/1K76 (data not shown). The
additional selection of arginine at PfCRT position 72, or to
lysine or arginine at position 352, abrogated the effects of
the position 76 isoleucine on drug interactions.
CQ IC50 values correlate with charge change and amino
acid hydropathy at PfCRT position 76
An earlier bioinformatic analysis predicted that parasite
susceptibility to desethylamodiaquine and the extent of
VP chemosensitization to CQ would relate to the hydropa-
thy of mutable PfCRT amino acids (Warhurst, 2003). To
test this prediction, we examined the relationship of CQ
Fig. 4. Schild regression indicates a competitive interaction between QN and VP in the 106/176I line.
A. Changes in QN dose–response curves in the presence of different concentrations of VP. Shifts to the right in the dose–response curves
highlight the inhibitory effect of VP against QN. Values represent means  SEM from three independent assays.
B. Linear Schild regression plot derived from dose–response data. The slope is not significantly different from unity (0.9689; 95% confidence
interval = 0.8833–1.054), indicating a simple competitive interaction between QN and VP. The X-intercept predicts an equilibrium dissociation
constant (KB) of 324 nM (95% confidence interval = 289–358 nM) for VP with its binding site.
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IC50 values to hydropathy at position 76 as an indication of
the hydrophobic and hydrophilic tendencies of these
amino acids to affect drug susceptibility. Figure 6A shows
a sharp increase in CQ IC50 value with the loss of charge
and slight change in hydropathy corresponding to the
lysine to asparagine substitution at position 76. The IC50
values of the CQ-resistant mutants track with the increas-
ing hydropathies of asparagine, threonine and
isoleucine respectively. We discerned no relationship
between CQ IC50 values and side-chain volumes of the
different amino acids at position 76 (Fig. 6B). In a similar
analysis, no associations between amino acid 76 hydr-
opathy or volume and QN or QD susceptibilities were
detected (data not shown).
Discussion
Genetic linkage studies have shown that point mutations
in the pfcrt gene of P. falciparum determine VP-reversible
CQR as well as specific susceptibilities and cross-
Fig. 5. The PfCRT K76I mutation alters quinoline drug interactions. Isobolograms illustrating the effects of amino acid changes at PfCRT
position 76 on quinoline drug combinations in the 106/1K76 line of P. falciparum. Data points represent the fractional IC50 values of various dose
combinations of CQ:QN, CQ:QD and QN:QD. Points near the solid line indicate an additive relationship between the two drugs, those above
the line indicate antagonism and those the below the line indicate a synergistic relationship. The plotted data show that interactions involving
QN become highly synergistic following a K76I mutation. Each isobologram was derived from a series of three independent dose–response
experiments; data points from all experiments are shown.
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resistance of this parasite to other quinoline antimalarials
(Fidock et al., 2000; Sidhu et al., 2002). However, neither
the precise manner in which PfCRT functions in drug
resistance nor its endogenous substrates are known. In
the absence of systematic mutagenesis of pfcrt in a con-
trolled genetic background, studies of the contributions of
single-point mutations on drug responses have been
limited to a small number of changes at position 76
(Cooper et al., 2002; Lakshmanan et al., 2005). Here, we
have used single-step drug selection with QN or CQ to
generate a panel of novel PfCRT mutants. Selection of
these mutants provided a unique opportunity to investi-
gate the relationship between drug potency and amino
acid changes in previously unexplored domains of PfCRT.
Our results indicate that PfCRT residues in positions 72
and 76 of TMD 1 and position 352 of TMD 9 are involved
in a drug recognition site critical to the VP-reversible CQR
phenotype. In addition to their effect on the CQ pheno-
type, the physicochemical properties of these key amino
acids also affect quantitative responses to other important
quinoline antimalarial drugs such as QN and QD. Our
study detected no mutations in pfmdr1, whose putative
P-glycoprotein-like product (Pgh1) may modulate levels of
response to certain DV-targeting drugs (Duraisingh and
Cowman, 2005; Sidhu et al., 2005).
In our single-step selection experiments with CQ or QN,
the concentration of drug used was rapidly lethal to the
drug-sensitive parental 106/1K76 or 106/176I line, prevent-
ing proliferation of parasites without adaptive changes.
With sufficiently large parasite populations, however, it
was possible to select parasite(s) that had incurred a
spontaneous point mutation capable of conferring resis-
tance to the media concentration of the drug. Gassis and
Rathod (1996) showed that 105-108 parasites are
required to select resistance to atovaquone and
5-fluororotate. In other experiments with 100 nM CQ pres-
sure on the 106/1K76 line, we found that single mutations in
pfcrt emerged at a rate of one per ~1010 drug-sensitive
parasites (Cooper et al., 2002). Using single-step drug
selection, the probability of simultaneously selecting addi-
tional point mutations specifically required for resistance
is considered to be multiples of the mutation frequency
(Rathod et al., 1997). Although unlikely, we cannot entirely
rule out the possible selection of mutations in genes other
than pfcrt and pfmdr1 and their role in the phenotypic
changes we observe in our selected lines.
In contrast to these single-step selection experiments,
Johnson et al. (2004) used long-term, incremental pres-
sure with halofantrine and amantadine, drugs that show
an inverse potency relationship with CQ in P. falciparum,
to identify new pfcrt mutants from a CQ-resistant line.
Amantadine pressure selected a parasite line carrying two
PfCRT changes: a novel S163R mutation in TMD 4 and a
previously undocumented I356V substitution. Halofan-
trine pressure also selected S163R, along with two other
mutations: T152A and P275L. With the acquisition of
amantadine or halofantrine resistance, both lines showed
a return to CQS and a loss of the VP-reversible pheno-
type, changes consistent with gain of a positive charge in
the PfCRT pore from the S163R change. The multiple
mutations in pfcrt, and perhaps mutations in other genes
of these cell lines, may have occurred in a cumulative
manner under long-term exposure to sublethal drug
concentrations.
In our earlier attempts at single-step CQ selection with
the 106/1K76 line, we recovered K76N and K76I but not the
predominant field K76T mutation (Cooper et al., 2002).
K76T was, however, obtained in the experiments reported
here, consistent with the probability of its eventual selec-
tion in repeated experiments. As expected, the selected
106/176T parasites exhibited a typical VP-reversible phe-
notype of CQR, and showed a 13-fold increase in the CQ
IC50, a 22-fold decrease in cellular accumulation of
[3H]CQ, and similar expression levels of PfCRT when
compared with the 106/1K76 parent (Table 1; Figs 2B and
3). As observed previously, the six PfCRT mutations
Fig. 6. CQ resistance correlates with charge loss and hydropathy of PfCRT position 76 residues.
A. CQ IC50 plotted as a function of Kyle–Doolittle hydropathy. Mean CQ IC50 values are significantly different between all four lines (P < 0.05;
unpaired t-tests; Table 1), and slope for the regression of N, T and I versus CQ IC50 is non-zero (P < 0.05). Letter abbreviations for the
corresponding amino acids are shown adjacent to the data points on the graph.
B. No relationship was observed between mean CQ IC50 values and side-chain volume of the position 76 amino acids.
276 R. A. Cooper et al.
© 2006 The Authors
Journal compilation © 2006 Blackwell Publishing Ltd, Molecular Microbiology, 63, 270–282
outside of position 76 did not provide any significant
increase in the CQ IC50 of the 106/1K76 parent relative to
other CQ-sensitive parasite lines (Cooper et al., 2002).
CQR from each of the various K76T, K76I and K76N
mutations supports the hypothesis that other PfCRT
changes are compensatory mutations and that the loss of
the critical charged lysine residue at position 76 dictates
the large IC50 change that results in clinical resistance.
Wild-type PfCRT carries a positively charged lysine at
position 76 in TMD 1 predicted to lie near the luminal face
of the DV (Fidock et al., 2000; Martin and Kirk, 2004).
Passive efflux of CQ2+ out of the DV through wild-type
PfCRT may be blocked by a charge-repulsion effect due to
the presence of the K76 residue, an idea that has been
incorporated into a proposal for resistance termed the
‘charged drug leak’ model (Warhurst, 2003; Johnson et al.,
2004; Bray et al., 2006). In this model, substitution of K76
by a neutral residue (76T, 76N or 76I) could allow exit of
CQ2+ out of the DV along its concentration gradient, dimin-
ishing availability of drug to bind its haem target, resulting
in loss of potency. VP, which selectively restores CQ
potency to resistant parasites, is predicted to bind to the
putative PfCRT channel in the vicinity of position 76. The
positive charge carried by VP under the acidic conditions of
the DV replaces that found on the wild-type 76 lysine,
re-establishing a charge-repulsion effect that retains CQ at
its target site (Warhurst et al., 2002). On the other hand, an
alternative model of energy-dependent CQ efflux has been
supported in reports of [3H]CQ kinetics in natural isolates
as well as transformed lines of P. falciparum (Krogstad
et al., 1992; Sanchez et al., 2004; 2005).
On the controlled genetic background of the 106/1K76
line, the relationships of the 76K, 76N, 76T and 76I resi-
dues in PfCRT to CQ IC50 levels suggests an effect of
amino acid hydropathy as well as charge in CQ response
(Fig. 6A). In the case of QN or QD, however, the IC50
levels of the 106/1K76, 106/176N, 106/176I and 106/176T lines
(Table 1) do not suggest charge or hydropathy relation-
ships similar to those for CQ. Instead, the increased
potency of QN relative to QD against 106/176I and the
effect of VP to increase rather than decrease QN potency
(Table 1) points to a complex stereospecific interaction
between PfCRT and QN or QD that predominates over a
simple weak-base trapping effect.
Stereoselectivity of the cinchona alkaloids against Plas-
modium and in other pharmacological systems is well
known, highlighting the importance of specific drug–
receptor interactions in their activity (Notterman et al.,
1986; Sheldon et al., 1990; Wigler and Patterson, 1994;
Munoz et al., 1996; Karle and Bhattacharjee, 1999; Hoo-
iveld et al., 2002). A possible explanation for the dramatic
increase in QN potency against 106/176I is a shift to a net
inward, as opposed to outward movement of QN through
PfCRT (Fig. 7). This explanation is consistent with our
evidence that the K76I mutation leads to an increased
cellular QN accumulation but decreased QD accumula-
tion relative to 106/1K76 (Cooper et al., 2002). This expla-
nation also accounts for the inhibition rather than
chemosensitization of QN activity in 106/176I parasites by
VP (Table 1; Fig. 4A). In accord with an influx of QN
through PfCRT, bound VP would inhibit, rather than poten-
tiate the QN response simply by reducing accumulation of
QN in the DV. Indeed, analysis of this antagonistic rela-
tionship between VP and QN in 106/176I by Schild regres-
sion suggests a simple competitive interaction for a
common binding site at PfCRT (Fig. 4B). Additionally, the
transition from additivity or antagonism in the 106/1K76 and
106/176T lines to strongly synergistic interactions between
QN and QD or CQ in 106/176I attest to a unique interaction
between QN and PfCRT that influences CQ and QD activ-
ity in this line (Fig. 5).
When combined, CQ and QN have been reported to be
antagonistic in P. falciparum, both in vitro and in vivo (Hall,
1973; Stahel et al., 1988). In contrast, Wesche and Black
(1990) demonstrated that combinations of the cinchona
alkaloid diastereomers QN–QD and cinchonine–
cinchonidine produced an additive effect against P. falci-
parum. In the case of QN and QD, an additive relationship
is predicted when two such isomers possess identical
mechanisms of action, but differ in their affinity for a
common receptor site (Tallarida, 2001). In 106/176I,
Fig. 7. Illustration of a model of outward and inward movements of
QN through different mutant forms of PfCRT. In the CQR form of
PfCRT (K76T; top), VP is proposed to bind in the vicinity of the
putative PfCRT pore at the inner surface of the DV membrane.
When bound, VP may act to reduce active transport or passive
efflux of CQ out of the DV, partially restoring CQ sensitivity to
resistant lines (Warhurst et al., 2002). In the case of the CQR
mutant PfCRT K76I (bottom), however, VP acts oppositely as a
competitive inhibitor of QN, although it still potentiates the CQ and
QD response in the typical manner. A net inward movement of QN
through PfCRT, inhibitable by VP, could account for these
observations as well as the hypersensitivity to QN in the 106/176I
line. PfCRT position 76 is predicted to occur in TMD 1 and form
part of the protein pore at the interior membrane surface of the DV.
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however, a net inward movement of QN through PfCRT
may act to reduce efflux of CQ or QD, resulting in high
levels of both drugs in the DV and a corresponding synergy.
In support of a model for a common drug efflux pathway,
Sanchez et al. (2004) demonstrated that QN and QD were
able to compete with CQ for transport from the DV by the
putative PfCRT efflux pathway. Our data indicate that
PfCRT position 76 contains a critical residue affecting
interaction with QN and QD, and suggest that the K76I form
of PfCRT mediates movement of QN in the opposite direc-
tion from QD through discriminating interactions with
unique features of each drug’s stereoisomeric structure.
Careful studies tracking the intracellular movement of
radiolabelled QN and QD in relation to pfcrt mutations will
be required to verify the hypothesis that PfCRT can
mediate both the inward and outward movement of drug.
The extreme sensitivity to QN of 106/176I (IC50 = 16 nM)
suggested opportunities for additional informative experi-
ments of single-step selection with QN. Results of these
experiments identified three novel amino acid changes in
the 106/176I PfCRT sequence, C72R, Q352K and Q352R,
each of which re-introduced a positive charge into a TMD.
These changes resulted in increased levels of CQ accu-
mulation, and abrogated the stereoselective potentiation
of QN sensitivity by the K76I mutation. In the case of the
double mutants, the increase in CQ accumulation was not
as dramatic as might be predicted. Only the increased
accumulation of CQ by 106/176I-352K was significantly dif-
ferent from the 106/176I parent line (Fig. 3). Nonetheless, a
trend was observed between CQ accumulation levels in
the double-mutants and their respective CQ IC50 values
(Table 1, Fig. 3). As these lines were selected for QN
resistance rather than CQ resistance, the effect on CQ
phenotype in these unusual parasites may involve more
than simple changes in drug accumulation levels.
In the case of the QN-selected lines, the positive charge
of each mutation probably acts as a second-site suppres-
sor mutation to restore CQS, in agreement with earlier
observations on the effect of S163R mutations in PfCRT
TMD 4 of resistant P. falciparum lines carrying K76T
(Johnson et al., 2004). Positions 72, 163 and 352 are
found in TMDs 1, 4 and 9, respectively, and their identifi-
cation as second-site suppressors with respect to the CQ
response suggests that they are in or near a drug recog-
nition domain. Our observation that the C72R mutation
can compensate for K76 and restore CQS to 106/176I
indicates that 72 and 76 are in proximity to each other
within TMD 1, although at slightly different depths within
the membrane (Fig. 8). Lakshmanan et al. (2005) have
shown that residues 72, 74 and 75 are important to the
level of VP reversibility of both CQ and QN in genetically
transformed parasites. As pointed out above, the effect of
an arginine versus a lysine residue at position 352 in TMD
9 resulted in retention of CQR-like properties in the 106/
176I-352R line (Table 1). As both mutant lines 106/176I-352K
and 106/176I-352R differ from 106/176I by replacement of the
polar, uncharged side-chain of glutamine by a positively
charged side-chain, the functional chemistry of this
residual phenotype is likely to involve structural features
of arginine not present in lysine. Relative to lysine, argin-
ine is of greater peptide mass (156 versus 128) and
carries a more delocalized positive charge in a complex
guanidinium group at the end of a shorter carbon-
containing stretch in the side-chain. The amino acid side-
chain volume contribution of arginine is consequently only
slightly greater than that of lysine (173.4 and 168.6 Å3,
respectively; Zamyatnin, 1972) while its hydropathy index
suggests an even greater tendency than that of lysine to
prefer a polar environment (-4.5 versus -3.9; Kyte and
Doolittle, 1982). Taken together, these results provide
strong evidence that CQ accumulation and susceptibility
depend on the presence of a critical positive charge,
placed at or near the drug binding site of PfCRT in the
form of a lysine or arginine residue in TMD 1, 4 or 9.
Within the drug metabolite effluxer (DME) branch of the
DMT superfamily, of which the Plasmodium CRT proteins
are predicted members, TMDs 1, 4 and 9 often contain
binding motifs required for substrate recognition and
translocation (reviewed by Martin and Kirk, 2004). The
drug phenotype changes attributable to mutations in
these regions of PfCRT are consistent with such findings.
To gain further insight into the structural significance of the
novel mutations reported here and from other studies, we
modelled TMDs 1, 4 and 9 of PfCRT as alpha-helices,
representing 3.6 amino acid residues per turn (Fig. 8)
(Arai et al., 2004). The wheel projections predict an
amphipathic character for the helices, suggesting that
they may border a pore in the DV membrane. The polar
sides of the helices would form part of a hydrophilic face
of the pore, where amino acids 72, 76, 163 and 352 are
predicted to occur and likely to interact with drug. In this
structural context, mutations affecting the distribution of
charge and molecular properties of the pore could deter-
mine PfCRT’s affinity for drug substrates and possibly
their direction of net flux into or out of the DV.
We have demonstrated that CQ susceptibility is related
to charge changes within TMD 1, 4 or 9, as well as
hydropathy of the substituent amino acid at position 76.
Although the data do not necessarily discriminate
between active or passive efflux mechanisms, they do
indicate that direct PfCRT–drug interactions are critical to
the loss of CQ from the DV. With respect to QN and QD
susceptibilities, however, the evidence for drug binding
appears more consistent with a selective transport
process as opposed to a passive leak model based on
charge loss or gain mutations. In either scenario the activ-
ity of PfCRT appears to be highly dependent on drug
structure, as the susceptibility changes to CQ, QN and
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QD are distinct. While our results implicate a critical role
for PfCRT–drug interactions in quinoline susceptibility,
additional studies will be required to determine the exact
mechanism by which PfCRT operates in drug flux.
Experimental procedures
Plasmodium falciparum culture
Parasites were grown in AB+ or O+ human red blood cells
using RPMI 1640 supplemented with 0.5% Albumax I
(Invitrogen, Carlsbad, CA), 0.25% sodium bicarbonate and
0.01 mg ml-1 gentamicin under an atmosphere of 90% nitro-
gen, 5% oxygen and 5% carbon dioxide. Parasites synchrony
was maintained by treatment with 5% sorbitol solution
(Lambros and Vanderberg, 1979).
Single-step selection for CQ and QN resistance
Single-step selection was carried out based on the methods
of Rathod et al. (1997) and Cooper et al. (2002). Parasites of
the 106/1K76 or 106/176I line were initially grown under normal
culture conditions, at 5% haematocrit, without the presence
of drug. When a 50 ml volume of culture reached a parasi-
taemia of ~5%, it was split equally into four flasks, and
restored to a volume of 50 ml and haematocrit of 5% with
fresh red blood cells and media. Cultures were maintained
until again reaching ~5% parasitaemia (representing ~109
parasites per flask), at which time either 100 nM CQ (106/
1K76) or QN (106/176I) was added. This concentration was
sufficient to rapidly kill any parasites except a possible pre-
existing, drug-resistant mutant. Drug-containing medium was
replaced daily for the first week. At 7 days post drug, 50% of
the remaining red blood cells were replaced with fresh cells.
Following day 7, culture medium was replaced every third
day with fresh drug-media, at which time cultures were moni-
tored for the presence of any emergent parasites by exam-
ining Giemsa-stained thin films. Fifty per cent of the red blood
cells were replaced at every other medium change until the
end of the experiment. In all cases, parallel, drug-free cul-
tures were maintained to monitor laboratory culture
conditions. Drug-pressured cultures were monitored for
60 days or until living parasites were observed. Emergent
Fig. 8. Helical wheel projections of PfCRT TMDs 1, 4 and 9. Projections of TMDs 1, 4 and 9 predict the amphipathic nature (a predominantly
polar and hydrophobic side) of the membrane spanning alpha-helices. In each case, the charged residues associated with CQ response lie in
the polar region of the helices, suggesting the polar faces may be oriented towards a pore or channel where they interact with substrates and
drugs. The hydrophobic faces may be associated with membrane lipid or other apolar surfaces. Residue numbers correspond to the positions
of residues in relation to the outside surface of the DV membrane. Arrows indicate alternative mutations associated with the CQ response.
The S163R mutation in TMD 4 was reported by Johnson et al. (2004).
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parasites from any positive flask were cloned by limiting
dilution (Rosario, 1981). Clonal parasites were processed for
genomic DNA preparations, cryopreservation and grown for
antimalarial dose–response assays.
Microsatellite genotyping and sequencing of pfcrt and
pfmdr1
The entire open reading frame sequences of pfcrt and pfmdr1
were amplified from genomic DNA. After treatment with
ExoSAP-IT (US Biochemical, Cleveland OH), polymerase
chain reaction products were directly sequenced on an ABI
3730XL automatic DNA analyser (Applied Biosystems, Foster
City, CA) using specific internal primers (Mu et al., 2003).
DNA from parasite clones was genotyped using the multicopy
microsatellite marker PfRRM as described. (Su et al., 1998;
Vieira et al., 2004). Electropherograms were analysed using
the GeneScan 3.7 software package (Applied Biosystems).
SDS-PAGE and immunoblotting
Crude membrane fractions of trophozoite-stage parasites for
SDS-PAGE were prepared from synchronous cultures. Tro-
phozoites were isolated from red blood cells using 0.1%
saponin. Parasite pellets were freeze-thawed three times,
after which the insoluble portion was pelleted by centrifugation
at 14K r.p.m. for 10 min. Pellets were solubilized with reducing
SDS-PAGE loading buffer and heated to 95°C for 5 min.
Protein samples representing ~4 ¥ 106 trophozoites were
separated on 12% polyacrylamide gels and transferred to
PVDF membrane. Membranes were incubated with affinity-
purified anti-PfCRT polyclonal antisera (anti-PfCRT K IgG;
Fidock et al., 2000) or anti-a-tubulin II antibody (MRA-37 MR4,
Manassas, VA) (Rohrbach et al., 2006) diluted 1:1000 over-
night at 5°C. Proteins were detected by chemiluminescence
(Pierce Biotechnology, Rockford, IL) following incubation with
rabbit horseradish peroxidase-conjugated secondary anti-
body (Jackson ImmunoResearch, West Grove, PA).
Drug susceptibility testing
The in vitro antiparasitic effect of the various drugs was
measured by [3H]-hypoxanthine (PerkinElmer Life Sciences,
Boston, MA) incorporation (Desjardins et al., 1979; Ferdig
et al., 2004). Per cent inhibition of growth was plotted against
log drug concentration to generate dose–response curves.
The half-maximal inhibitory response (IC50), defined as the
drug concentration at which growth was inhibited by 50%,
was estimated by curve-fitting the response data with a
variable-slope sigmoidal function (Prism 4.0c; GraphPad
Software, San Diego, CA). VP was used at a fixed concen-
tration of 0.9 mM in reversibility assays. Dose–response
curves represent 3–18 independent assays. Relevant IC50
values from single-drug assays were tested for statistical
significance by comparing mean values from each mutant
line to that of its parent line by an unpaired t-test (P < 0.05).
Mean Hill slope values between parasite lines were tested for
statistical significance using an F-test (P < 0.05).
For drug combination testing, drugs were mixed in volumet-
ric ratios of 9:1, 7:3, 1:1, 3:7 and 1:9. The starting unmixed drug
concentrations, CQ 2.5 mM; QN 2.5 mM; QD 625 nM, were
determined from single-drug assays that allowed the IC50 to be
centred in the test plate. Single drugs and drug combinations
were serially diluted twofold across the 96-well plate prior to
adding parasite culture. Results from the dose–response
curves were expressed as sums of the fractional IC50 (FIC)
values and plotted as isobolograms (Berenbaum, 1978). FIC
values < 1 indicate synergism, those equal to 1 indicate addi-
tivity and those > 1 indicate antagonism. Experiments were
repeated on three independent occasions, with data from all
experiments shown on the plots.
To determine the mechanism of QN inhibition by VP in the
106/176I line, Schild analysis was performed (Arunlakshana
and Schild, 1959). A series of QN dose–response curves was
generated in the presence and absence of fixed concentra-
tions of VP and fit by non-linear regression. Data derived from
the dose–response curves were plotted as log(dose ratio - 1)
as a function of the log VP concentration. Dose ratio was
defined as the equi-active concentration of QN in the pres-
ence of VP divided by the concentration of QN in the absence
of VP. Linear regression was performed to derive the Schild
regression and provide an estimate of the KB for VP binding.
Data were derived from a total of three independent tests of
the QN with VP dose–response series.
[3H]CQ accumulation assays
Chloroquine accumulation was determined by incubating
trophozoite-infected erythrocytes with 50 nM [3H]CQ (Amer-
sham Biosciences, Piscataway, NJ) and processed as
described (Cooper et al., 2002). Parasites were collected at 0
and 60 min for [3H]CQ uptake measurements. Cellular accu-
mulation ratio (CAR) was determined by dividing the amount
of [3H]CQ measured in infected erythrocytes by the [3H]CQ
measured in a similar number of uninfected erythrocytes.
Accumulation experiments were conducted on three to four
independent occasions, with each assay conducted in
duplicate. A t-test was performed to determine whether mean
CAR values between relevant parasite lines were signifi-
cantly different (P < 0.05).
Correlation of amino acid physicochemical properties
with drug response
Hydrophobicity values were from the consensus scale of Kyte
and Doolittle (1982). Side-chain volumes were from Zamyat-
nin (1972). Physical parameters for each of the four different
amino acids at PfCRT position 76 (K, N, T, I) were plotted
versus the CQ IC50 values. Linear regression analysis was
performed using Prism 4 software. Slope values were tested
for statistical differences from zero (P < 0.05).
Secondary structure predictions
Putative transmembrane domains and helical projections
were derived using ConPred II (http://bioinfo.si.hirosaki-u.ac.
jp/~ConPred2/), a web-based algorithm for predicting sec-
ondary structure of transmembrane proteins. Conpred II is a
consensus method that utilizes multiple topology prediction
methods (Arai et al., 2004).
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